Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | CASR | P41180 | 8/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1105981 | 0.93 | ACHE (0.43) | ACHESIGMAR1CASRACKR3KDM1A | |
| SCHEMBL1106032 | 0.92 | CASR (0.45) | CASRACKR3KDM1AMAOB | |
| SCHEMBL1106062 | 0.90 | CASR (0.42) | CASRACKR3KMT2A | |
| SCHEMBL1106035 | 0.90 | ACKR3 (0.46) | ACHECASRACKR3KMT2A | |
| SCHEMBL1105889 | 0.90 | DRD4 (0.47) | SIGMAR1CASRACKR3KDM1AMAOB | |
| SCHEMBL1105967 | 0.89 | DRD4 (0.46) | ACHESIGMAR1CASRKMT2A | |
| SCHEMBL1105968 | 0.89 | ACKR3 (0.46) | SIGMAR1CASRACKR3 | |
| SCHEMBL1105888 | 0.89 | CCR5 (0.44) | SIGMAR1CASRACKR3 | |
| SCHEMBL1106057 | 0.89 | DRD2 (0.42) | SIGMAR1CASRACKR3 | |
| SCHEMBL1105965 | 0.89 | CASR (0.42) | ACHESIGMAR1CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153658-B2 | Piperidine derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-8153658-B2 | Piperidine derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-02-04 | — | — | US | disclosed |
| EP-2085383-A1 | PIPERIDINE DERIVATIVES OR SALTS THEREOF | Astellas Pharma Inc. (JP) | 2009-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | CASR, CYP2R1, HCAR1 | ACHE 4094/4885SIGMAR1 433/4885CASR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.